Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563887 | 0.84 | MGMT (0.35) | MGMTGAA | |
| SCHEMBL3126071 | 0.82 | CA2 (0.32) | CA2 | |
| SCHEMBL21205133 | 0.81 | CA2 (0.31) | CA2 | |
| SCHEMBL9323171 | 0.80 | RAB9A (0.38) | MAPTHPGDGAA | |
| SCHEMBL3130891 | 0.79 | CA2 (0.33) | CA2 | |
| SCHEMBL3790167 | 0.78 | HPGD (0.47) | MAPTHPGDGAA | |
| SCHEMBL17410684 | 0.77 | BACE1 (0.33) | CA2 | |
| SCHEMBL3125082 | 0.77 | — | — | |
| SCHEMBL3134032 | 0.77 | ALDH1A1 (0.30) | — | |
| SCHEMBL1244136 | 0.77 | SLC6A4 (0.37) | MGMTSLC6A4SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3517112-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009074789-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MGMT 2887/4885CA2 4377/4885MAPT 2189/4885 |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | MGMT 35/4885CA2 1862/4885MAPT 4332/4885 |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | MGMT 2887/4885CA2 4377/4885MAPT 2189/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | MGMT 4488/4885CA2 2539/4885MAPT 1609/4885 |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MGMT 2887/4885CA2 4377/4885MAPT 2189/4885 |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MGMT 2887/4885CA2 4377/4885MAPT 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.